Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Introduction of Soluble Urokinase Plasminogen Activating Receptor in Acute Care as a Prognostic Biomarker to Strengthen Risk Stratification of Acutely Admitted Patients

NCT02643459 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.

NCT NCT02643459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02643459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Introduction of Soluble Urokinase Plasminogen Activating Receptor in Acute Care as a Prognostic Biomarker to Strengthen Risk Stratification of Acutely Admitted Patients
Lead sponsor
Herlev Hospital
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2016
Completion date
April 6, 2017
Enrollment
20,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

risk stratification with biomarker, triage